Author: PharmaSignal News Desk

Precigen FDA approval for Papzimeos granted without confirmatory trial, benefiting adult patients with recurrent respiratory papillomatosis.

AbbVie acquires bretisilocin for up to $1.2 billion, marking a significant move in psychedelic treatments.

LB Pharmaceuticals IPO raises $285M, marking the first major biotech IPO since February, focusing on schizophrenia treatment.

Novartis Monte Rosa partnership focuses on immunology, potentially worth $5.7 billion.

FDA guidance non-opioid pain medicines includes speedy approval pathways to address the opioid crisis with new drug options.

Sun Pharma Halol Plant faces an FDA export ban due to ongoing safety violations, affecting drug exports to the US.

Takeda appoints Rhonda Pacheco to lead its U.S. business, leveraging her experience with Zepbound’s launch.

Novo Nordisk layoffs affect 9,000 employees globally as part of restructuring to address obesity drug competition.

Merck cancels London lab plans, citing $1.3B investment issues and lack of UK government progress.

FDA pig organ trial to start next year, advancing gene-edited organs in humans. Key step in transplantation.